Johnson & Johnson Strikes $850 Million Deal to Boost Dermatology Portfolio

By Colin Kellaher


Johnson & Johnson has agreed to buy privately-held biotechnology company Proteologix for an initial $850 million in cash in a deal that bolsters the healthcare giant's...

Related Keywords

Colin Kellaher ,Johnson ,New Brunswick ,Dow Jones ,